Bakuchiol
Based on 2 publication(s) in Google Scholar
Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2) , with IC50s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory, antibacterial, antitumor therapies, as well as drug metabolism regulation.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.08%
- No. CAS: 10309-37-2
- Fòrmula: C18H24O
- Peso molecular:256.38
-
Almacenamiento:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Bakuchiol
More
Actividad biológica
IC50:40.9 nM (UGT2B7) ; IC50:7.28 nM (hCE2)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| AGS | IC50 |
15.3 μM
Compound: 1
|
Cytotoxicity against human AGS cells by MTT assay
Cytotoxicity against human AGS cells by MTT assay
|
[PMID: 18359631] |
| AGS | IC50 |
6.1 μM
Compound: 1
|
Inhibition of hypoxia-induced HIF1 activation in human AGS cells by reporter gene assay
Inhibition of hypoxia-induced HIF1 activation in human AGS cells by reporter gene assay
|
[PMID: 18359631] |
| BJ | EC50 |
>36.63 μM
Compound: 1
|
Cytotoxicity against human BJ cells after 72 hrs by Cell-Titer Glo assay
Cytotoxicity against human BJ cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 26922230] |
| HEK293 | EC50 |
>36.63 μM
Compound: 1
|
Cytotoxicity against HEK293 cells after 72 hrs by Cell-Titer Glo assay
Cytotoxicity against HEK293 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 26922230] |
| HeLa | IC50 |
11 μM
Compound: 1
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 18359631] |
| HeLa | IC50 |
6.9 μM
Compound: 1
|
Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells
Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells
|
[PMID: 18359631] |
| HepG2 | EC50 |
>52.0833 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
Cytotoxicity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 26922230] |
| Jurkat | EC50 |
>49.0196 μM
Compound: 1
|
Cytotoxicity against human Jurkat cells after 72 hrs by Cell-Titer Glo assay
Cytotoxicity against human Jurkat cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 26922230] |
| MDA-MB-231 | IC50 |
8.29 x 10-3 mol/L
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 22245048] |
| MDA-MB-231 | IC50 |
8.29*10-3 M
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 22245048] |
| NALM-6 | EC50 |
38 μM
Compound: 1
|
Cytotoxicity against human NALM6 cells after 72 hrs by Cell-Titer Glo assay
Cytotoxicity against human NALM6 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 26922230] |
| Raji | EC50 |
>26.0417 μM
Compound: 1
|
Cytotoxicity against human Raji cells after 72 hrs by Cell-Titer Glo assay
Cytotoxicity against human Raji cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 26922230] |
| RAW264.7 | IC50 |
97.23 μM
Compound: BAK
|
Cytotoxicity against mouse RAW 264.7 cells assessed as decreased cell viability measured after 24 hrs by MTT assay
Cytotoxicity against mouse RAW 264.7 cells assessed as decreased cell viability measured after 24 hrs by MTT assay
|
[PMID: 35000392] |
| SEM | EC50 |
15.2866 μM
Compound: 1
|
Cytotoxicity against human SEM cells after 72 hrs by Cell-Titer Glo assay
Cytotoxicity against human SEM cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 26922230] |
| T47D | IC50 |
2.89 x 10-5 mol/L
Compound: 1
|
Cytotoxicity against human T47D cells
Cytotoxicity against human T47D cells
|
[PMID: 22245048] |
| T47D | IC50 |
2.89*10-5 M
Compound: 1
|
Cytotoxicity against human T47D cells
Cytotoxicity against human T47D cells
|
[PMID: 22245048] |
Bakuchiol (5-20 μM, 72 h) exhibits selected cytotoxicity in A549 cells, as determined by the MTT assay. Bakuchiol displays stronger effect than its analogue Resveratrol (HY-16561) in reducing the viability of A549 cells with IC50s vales of 9.58 μM and 33.02 μM, respectively[1]. Bakuchiol (5-20 μM, 24 h or 36h) blocks cell cycle progression at S phase and induction of Reactive Oxygen species (ROS) -related apoptosis (more importantly) in A549 cells in a concentration-dependent manner[1]. Bakuchiol (0-80 μM, 120 min) is a non-competitive inhibitor of UDP-glucuronosyltransferase 2B7 (UGT2B7) with Ki value of 10.7 μM and IC50 value of 40.9 μM[2]. Bakuchiol (30 min) is a potent non-competitive inhibitor of human carboxylesterase 2 (hCE2) with low Ki value of 2.12 μM and IC50 value of 7.28 μM[3]. Bakuchiol (0.9775-3.91 μg/mL, 24 h) demonstrates a significant dose-dependent increase in membrane permeability of the fungal conidia of T. mentagrophytes[4]. Bakuchiol (3.91 μg/mL, 3 h) elicites a 187% elevation in Reactive Oxygen species (ROS) level in fungal cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells, EA.hy926 cells, HUVEC cells and MEF
-
Concentration:5, 10, and 20 μM
-
Incubation Time:24 hours
-
Result:Induced caspase 9/3 activaton, p53 and Bax up-regulation, as well as Bcl-2 down-regulation.
-
Cell Line:A549 cells, EA.hy926 cells, HUVEC cells and MEF
-
Concentration:5, 10, and 20 μM
-
Incubation Time:36 hours
-
Result:Resulted in typical apoptotic cells (p < 0.05), as determined by Annexin V/propidium iodide staining and flow cytometry.
-
Cell Line:A549 cells
-
Concentration:5, 10, and 20 μM
-
Incubation Time:24 hours
-
Result:Increased S phase cell population accompanied with a concomitant reduction of cells in the G1 phase. Resulted in a less potent effect in S phase arrest than bakuchiol.
-
Cell Line:A549 cells, EA.hy926 cells, HUVEC cells and MEF
-
Concentration:5, 10, and 20 μM
-
Incubation Time:72 hours
-
Result:Inhibited the growth of A549 cells, while the growth rate of other cells were not changed. Exhibited concentration-dependent cytotoxicity in A549 cells, while bakuchiol showed a more potent effect than that of resveratrol with IC50s vales of 9.58 μmol/L and 33.02 μmol/ L, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:OVA -induced AR model (BALB/c mice, 6-week-old) [5]
-
Dosage:10 and 20 mg/kg
-
Administration:Oral route (p.o.)
-
Result:Reduced the nasal symptoms and decreased the levels of IL-4, IL-5, IL-13, Igs (IgE and IgG1), histamine, IL-10, IL-33, and TNF-α. Reduced PGDA and LTC-4 levels in the nasal lavage fluid (NLF). Decreased the ROS and MDA levels, whereas boosting SOD activity. Decreased the eosinophil count in the nasal tissues and influenced the Th1 and Th2 cell proportions.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 10309-37-2
-
Appearance Liquid (Density: 0.963 g/cm3)
-
Peso molecular 256.38
-
Fòrmula C18H24O
-
Color Colorless to yellow
-
SMILES
OC1=CC=C(/C=C/[C@](C)(C=C)CC/C=C(C)\C)C=C1
-
Synonyms
(S)-(+)-Bakuchiol
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
2022 Nov 15:298:115593. PMID: 35973629 -
Chem Biol Interact
Bavachinin, a main compound of Psoraleae Fructus, facilitates GSDMD-mediated pyroptosis and causes hepatotoxicity in mice. [Abstract]2024 Sep 1:400:111133. PMID: 38969277
Solvente y solubilidad
DMSO : 62.5 mg/mL (243.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.17 mg/mL (8.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (458 KB)
- English - EN (458 KB)
- Français - FR (458 KB)
- Deutsch - DE (458 KB)
- Norwegian - NO (458 KB)
- Español - ES (458 KB)
- Swedish - SV (458 KB)
- Italian - IT (458 KB)
- Korean - KR (458 KB)
- Portuguese - PT (458 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Chen Z, et al. Anti-tumor effects of bakuchiol, an analogue of resveratrol, on human lung adenocarcinoma A549 cell line. Eur J Pharmacol. 2010 Sep 25;643(2-3):170-9. [Content Brief]
[2]. Xu Y, et al. In vitro evidence for bakuchiol's influence towards drug metabolism through inhibition of UDP-glucuronosyltransferase (UGT) 2B7. Afr Health Sci. 2014 Sep;14(3):564-9. [Content Brief]
[3]. Li YG, et al. Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxylesterase 2. Fitoterapia. 2015 Jan 13;101C:99-106. [Content Brief]
[4]. Lau KM, et al. Anti-dermatophytic activity of bakuchiol: in vitro mechanistic studies and in vivo tinea pedis-inhibiting activity in a guinea pig model. Phytomedicine. 2014 Jun 15;21(7):942-5. [Content Brief]
[5]. Yao HB, et al. Anti-Allergic and Anti-inflammatory Effects of Bakuchiol on Ovalbumin-Induced Allergic Rhinitis in Mice. Appl Biochem Biotechnol. 2024;196(6):3456-3470. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9005 mL | 19.5023 mL | 39.0046 mL | 97.5115 mL |
| 5 mM | 0.7801 mL | 3.9005 mL | 7.8009 mL | 19.5023 mL | |
| 10 mM | 0.3900 mL | 1.9502 mL | 3.9005 mL | 9.7512 mL | |
| 15 mM | 0.2600 mL | 1.3002 mL | 2.6003 mL | 6.5008 mL | |
| 20 mM | 0.1950 mL | 0.9751 mL | 1.9502 mL | 4.8756 mL | |
| 25 mM | 0.1560 mL | 0.7801 mL | 1.5602 mL | 3.9005 mL | |
| 30 mM | 0.1300 mL | 0.6501 mL | 1.3002 mL | 3.2504 mL | |
| 40 mM | 0.0975 mL | 0.4876 mL | 0.9751 mL | 2.4378 mL | |
| 50 mM | 0.0780 mL | 0.3900 mL | 0.7801 mL | 1.9502 mL | |
| 60 mM | 0.0650 mL | 0.3250 mL | 0.6501 mL | 1.6252 mL | |
| 80 mM | 0.0488 mL | 0.2438 mL | 0.4876 mL | 1.2189 mL | |
| 100 mM | 0.0390 mL | 0.1950 mL | 0.3900 mL | 0.9751 mL |
Bakuchiol Related Classifications
HY-N0235 Related Classifications
Powered by Bioz